Artificial intelligence, drug repurposing and peer review.,Nature Biotechnology

当前位置： X-MOL 学术 › Nat. Biotechnol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Artificial intelligence, drug repurposing and peer review.
Nature Biotechnology ( IF 46.9 ) Pub Date : 2020-09-14 , DOI: 10.1038/s41587-020-0686-x
Jeremy M Levin _{1,

2} , Tudor I Oprea _{3,

4,

5,

6} , Sagie Davidovich ₇ , Thomas Clozel ₈ , John P Overington ₉ , Quentin Vanhaelen ₁₀ , Charles R Cantor ₁₁ , Evelyne Bischof _{10,

12,

13} , Alex Zhavoronkov ₁₀

Affiliation

Ovid Therapeutics, Inc, New York, NY, USA.
Biotechnology Innovation Organization (BIO), Washington, DC, USA.
Department of Internal Medicine, University of New Mexico Health Sciences Center, Albuquerque, NM, USA.
Autophagy Inflammation and Metabolism Center of Biomedical Research Excellence, University of New Mexico Health Sciences Center, Albuquerque, NM, USA.
Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden.
Novo Nordisk Foundation Center for Protein Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
SparkBeyond, Netanya, Israel.
Owkin, Paris, France.
Medicines Discovery Catapult, Cheshire, UK.
Insilico Medicine, Hong Kong Science and Technology Park, Hong Kong, China.
Retrotope, Inc, Los Altos, CA, USA.
Shanghai University of Medicine and Health Sciences, College of Clinical Medicine, Shanghai, China.
Department of Advanced Biomedical Sciences, Federico II University of Naples, Naples, Italy.

Can traditional computational analysis and machine learning help compensate for inadequate peer review of drug-repurposing papers in the context of an infodemic?

中文翻译：